Resmed Names Salli Schwartz as Chief Investor Relations Officer
Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology, has appointed Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Reporting to CEO Mick Farrell, Schwartz brings over 20 decades of finance experience from health tech and financial services sectors.
Schwartz joins from Illumina, where she served as Head of Investor Relations, managing shareholder engagement, corporate strategy, and financial performance communications. Her previous roles include Head of IR and Treasurer at MSCI, managing over $2 billion in investments and $4 billion in debt, and various leadership positions at Moody's and Citigroup.
This appointment aligns with Resmed's 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential through better sleep and breathing health solutions.
Resmed (NYSE: RMD, ASX: RMD), leader globale nella tecnologia sanitaria, ha nominato Salli Schwartz Chief Investor Relations Officer, con effetto dal 21 aprile 2025. Riportando direttamente al CEO Mick Farrell, Schwartz vanta oltre 20 anni di esperienza nel settore finanziario e della tecnologia sanitaria.
Schwartz arriva da Illumina, dove ha ricoperto il ruolo di Responsabile delle Relazioni con gli Investitori, gestendo il coinvolgimento degli azionisti, la strategia aziendale e le comunicazioni sulle performance finanziarie. In precedenza è stata Head of IR e Tesoriere presso MSCI, con la gestione di investimenti superiori a 2 miliardi di dollari e debiti per 4 miliardi, oltre a ricoprire posizioni di leadership in Moody's e Citigroup.
Questa nomina è in linea con la strategia 2030 di Resmed, mirata a incrementare il valore per gli azionisti e a supportare 500 milioni di persone nel mondo a raggiungere il loro massimo potenziale di salute attraverso soluzioni per un sonno e una respirazione migliori.
Resmed (NYSE: RMD, ASX: RMD), líder mundial en tecnología sanitaria, ha nombrado a Salli Schwartz como Chief Investor Relations Officer, con efecto a partir del 21 de abril de 2025. Reportando al CEO Mick Farrell, Schwartz aporta más de 20 años de experiencia en finanzas en los sectores de tecnología sanitaria y servicios financieros.
Schwartz proviene de Illumina, donde fue Jefa de Relaciones con Inversionistas, gestionando la participación de accionistas, la estrategia corporativa y las comunicaciones sobre desempeño financiero. Sus roles anteriores incluyen Jefa de IR y Tesorera en MSCI, manejando más de 2 mil millones de dólares en inversiones y 4 mil millones en deuda, además de ocupar cargos de liderazgo en Moody's y Citigroup.
Este nombramiento está alineado con la estrategia 2030 de Resmed para impulsar el valor para los accionistas y ayudar a 500 millones de personas en todo el mundo a alcanzar su máximo potencial de salud mediante mejores soluciones para el sueño y la salud respiratoria.
Resmed (NYSE: RMD, ASX: RMD)는 건강 기술 분야의 글로벌 리더로서 Salli Schwartz를 2025년 4월 21일부로 최고 투자자 관계 책임자(Chief Investor Relations Officer)로 임명했습니다. Schwartz는 CEO Mick Farrell에게 보고하며, 건강 기술 및 금융 서비스 분야에서 20년 이상의 금융 경험을 보유하고 있습니다.
Schwartz는 Illumina에서 투자자 관계 책임자로 근무하며 주주 참여, 기업 전략, 재무 성과 커뮤니케이션을 관리했습니다. 이전에는 MSCI에서 IR 책임자 및 재무 담당자로서 20억 달러 이상의 투자와 40억 달러의 부채를 관리했으며, Moody's와 Citigroup에서 다양한 리더십 직책을 역임했습니다.
이번 임명은 Resmed의 2030 전략과 부합하며, 주주 가치를 높이고 전 세계 5억 명이 더 나은 수면 및 호흡 건강 솔루션을 통해 최대 건강 잠재력을 실현할 수 있도록 지원하는 목표를 담고 있습니다.
Resmed (NYSE : RMD, ASX : RMD), leader mondial des technologies de santé, a nommé Salli Schwartz au poste de Chief Investor Relations Officer, à compter du 21 avril 2025. Relevant du PDG Mick Farrell, Schwartz apporte plus de 20 ans d’expérience dans la finance, notamment dans les secteurs de la technologie de santé et des services financiers.
Schwartz rejoint Illumina, où elle était responsable des relations investisseurs, en charge de l’engagement des actionnaires, de la stratégie d’entreprise et des communications sur la performance financière. Elle a également occupé les postes de responsable des relations investisseurs et trésorière chez MSCI, gérant plus de 2 milliards de dollars d’investissements et 4 milliards de dollars de dette, ainsi que divers postes de direction chez Moody’s et Citigroup.
Cette nomination s’inscrit dans la stratégie 2030 de Resmed, visant à accroître la valeur pour les actionnaires et à permettre à 500 millions de personnes dans le monde d’atteindre leur plein potentiel de santé grâce à de meilleures solutions pour le sommeil et la santé respiratoire.
Resmed (NYSE: RMD, ASX: RMD), der weltweit führende Anbieter im Bereich Gesundheitstechnologie, hat Salli Schwartz mit Wirkung zum 21. April 2025 zur Chief Investor Relations Officer ernannt. Schwartz berichtet an CEO Mick Farrell und bringt über 20 Jahre Erfahrung im Finanzwesen aus den Bereichen Gesundheitstechnologie und Finanzdienstleistungen mit.
Schwartz kommt von Illumina, wo sie als Leiterin der Investor Relations tätig war und die Aktionärskommunikation, Unternehmensstrategie sowie Finanzberichterstattung verantwortete. Zuvor war sie Head of IR und Schatzmeisterin bei MSCI, wo sie Investitionen von über 2 Milliarden US-Dollar und Schulden in Höhe von 4 Milliarden US-Dollar verwaltete, sowie in verschiedenen Führungspositionen bei Moody's und Citigroup tätig.
Diese Ernennung steht im Einklang mit Resmeds 2030-Strategie, den Aktionärswert zu steigern und 500 Millionen Menschen weltweit zu befähigen, ihr volles Gesundheitspotenzial durch bessere Schlaf- und Atemwegslösungen zu erreichen.
- None.
- None.
Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO.
Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company’s investor engagement strategy, representing the company’s response to shareholders’ perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina’s Corporate Social Responsibility Executive Steering Committee and its Transformation Office.
“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Farrell. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”
Prior to Illumina, Schwartz served as Head of Investor Relations and Treasurer at MSCI, Inc., where she managed investor communications as well as a portfolio of over
“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For Media: | For Investors: | |
| Kristen Handley Slater | Mike Ott or Wendy Wilson | |
| news@resmed.com | investorrelations@resmed.com |
FAQ
What experience does Salli Schwartz bring to her new role at Resmed (RMD)?
How does Salli Schwartz's appointment align with Resmed's (RMD) 2030 strategy?
What were Salli Schwartz's key achievements at MSCI before joining Resmed (RMD)?
When will Salli Schwartz begin her role as Chief Investor Relations Officer at Resmed (RMD)?
What responsibilities will Salli Schwartz have in her new position at Resmed (RMD)?
